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ABSTRACT
Objective To determine the optimal range of increase in
haemoglobin concentration with treatment with
erythropoietins that is safe and is not associated with
mortality.
Design Retrospective cohort study. The analysis was
adjusted for several covariables with Cox regression
analysis with spline functions. Use of erythropoietins,
haemoglobin concentration, and covariables were
includedin a timevaryingmanner;variable selectionwas
based on the purposeful selection algorithm.
Setting Transplantation centres in Austria.
Participants 1794 renal transplant recipients recorded in
the Austrian Dialysis and Transplant Registry who
received a transplant between 1 January 1992 and 31
December 2004 and survived at least three months.
Main outcome measures Survival time and haemoglobin
concentration after treatment with erythropoietins.
Results The prevalence of use of erythropoietins has
increased over the past 15 years to 25%. Unadjusted
extended Kaplan-Meier analysis suggests higher
mortality in patients treated with erythropoietins, in
whom 10 year survival was 57% compared with 78% in
those not treated with erythropoietins (P<0.001). In the
treated patients there were 5.4 events/100 person years,
compared with 2.6 events/100 person years in those not
treated (P<0.001). After adjustment for confounding by
indication, comorbidities, comedication, and laboratory
readings, haemoglobin concentrations >125 g/l were
associated with increased mortality in treated patients
(hazard ratio 2.8 (95% confidence interval 1.0 to 7.9) for
haemoglobin concentration 140 g/l v 125 g/l), but not in
those not treated (0.7, 0.4 to 1.5). When haemoglobin
concentrations were 147 g/l or above, patients treated
witherythropoietinsshowedsignificantlyhighermortality
than those who were not treated (3.0, 1.0 to 9.4).
Conclusion Increasing haemoglobin concentrations to
above 125 g/l with erythropoietins in renal transplant
recipientsisassociatedwithanincreaseinmortality.This
increase was significant at concentrations above 140 g/l.
INTRODUCTION
AccordingtotheTransplantEuropeanSurveyonAne-
mia Management (TRESAM), which analysed data
from 72 transplant centres in 16 countries, 38.6% of
renal transplant patients are anaemic—that is, their
serum haemoglobin concentration is ≤120 g/l in
females and ≤130 g/l in males.
1 One in five severely
anaemic patients, defined as haemoglobin concentra-
tion ≤100 (females) or ≤110 g/l (males), respectively,
receivedtreatmentwitherythropoietins.Furthermore,
there was a strong correlation between graft function
and anaemia and use of erythropoietins. Of the
patients with a serum creatinine concentration
>176.8 μmol/l 60% were anaemic compared with
29% of those with concentrations ≤176.8 μmol/l
(P<0.01).
Until the first clinical trials were stopped because of
an unexplained higher mortality rate in patients trea-
tedwitherythropoietins,thistreatmentwasconsidered
safe and effective in correcting anaemia in many indi-
cations, including renal anaemia.
Two studies in patients with advanced chronic kid-
ney disease found a higher mortality or more cardio-
vascular events in patients in whom the haemoglobin
concentration had been normalised with
erythropoietins.
23In the CHOIR study by Singh and
colleagues, 1432 patients with chronic kidney disease
stage3or4wererandomlyassignedtoreceivedosesof
erythropoietins aimed at achieving target haemoglo-
bin concentrations of 135 g/l or 113 g/l and followed
for a median of 16 months.
2 Of the 222 composite
events, which included death, myocardial infarction,
andcongestiveheartfailure,125occurredinthehigher
concentrationgroupand97inthelowerconcentration
group (hazardratio1.34, 95%confidence interval1.03
to 1.74; P=0.03).
The CREATE trial by Druecke and coworkers
investigated 603 patients with chronic kidney disease
stage 4 for three years.
3 Participants were randomised
to target haemoglobin concentration ranges with ery-
thropoietins of 130-150 g/l or 105-115 g/l. Fifty eight
cardiovasulcar events occurred in the higher concen-
tration arm and 47 in the lower concentration arm
(P=0.20).
A randomised study of use of erythropoietins in
patientswithendstagerenaldiseasetreatedbyhaemo-
dialysis was published in 1998 and the follow-up
reported as a comment in 2008.
45The authors found
that more patients died and had non-fatal cardiac
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volume of 0.42 with erythropoietins compared with
the group with a packed cell volume of 0.30.
In 2003 the first clinical trials investigated whether
correction of anaemia with erythropoietins could
improve outcome of curative radiotherapy among
patients with head and neck cancer but found an
increase in mortality.
67 Similarly, patients with meta-
static breast cancer receiving first line chemotherapy
who were treated with 40000U epoetin alfa weekly
exhibited a higher death rate than patients who
received placebo.
8 The main concern in oncological
studies was that erythropoietins were associated with
tumour progressionand mortality. Thesituation isdif-
ferent in renal patients, in whom the main causes of
death are cardiovascular events.
Abouthalfofallprevalentpatientswithterminalfail-
ure of their native kidneys receive a renal transplant.
Nearlyallrecipientsofarenalallograft,however,exhi-
bit impaired glomerular filtration rates, and the 39%
rate of anaemia is thus not surprising. It remains
unclear whether the findings on target haemoglobin
concentrations and treatment with erythropoietins in
patients with chronic kidney disease (CREATE,
CHOIR) and haemodialysis patients (Normal Hema-
tocrit Study) also apply to renal transplant recipients.
The main reported advantage of erythropoietins and
anaemia correction was a better quality of life in the
domains of physical activity.
9 Transplant patients are
more active and thus would probably derive special
benefitfromcorrectionofanaemiaintermsofphysical
functioning.
Asthereisnorandomisedcontrolledtrialunderway
nor is it likely that there will be one done in the near
future we conducted a cohort study in a well main-
tained national database. We investigated whether
higherachievedhaemoglobinconcentrationswithery-
thropoietins are associated with increased mortality in
renal transplant patients.
METHODS
Patient population
We used data from patients recorded in the Austrian
(OEsterreichisches) Dialysis and Transplant Registry
(OEDTR) and Eurotransplant database who received
a renal allograft between 1 January 1992 and 30 Sep-
tember 2004 and survived at least three months.
Patients were followed up until 31 December 2004
because thereafter prescriptions for erythropoietins
and target ranges changed in renal transplant patients
because of the availability of results from the CHOIR
and CREATE studies of patients with advanced
chronic kidney disease. The registry was established
by the Austrian Society of Nephrology in 1970 and
has almost complete follow-up; only 17 patients have
beenlostsince1990.TheEurotransplantdatabasewas
established in 1968 and holds complete entries of
organ donor characteristics from transplants per-
formed in the Eurotransplant region.
Our sample comprised 1794 patients and an equal
number of grafts because we analysed only the first
transplant. Before 1992 almost no patients received
treatment with erythropoietins (fig 1). After 2004, the
prescription pattern of erythropoietins changed
becauseofavailabledatafromabstractsofrandomised
controlled trials in chronic kidney disease and dialysis
patients and therefore, despite availability of data on
survival status and comorbidities up to 2008, we used
the time range only up to the end of 2004 for analysis.
Variables and definitions of variables
All variables recorded in the database are annually
updated and are listed in the appendix (see bmj.com).
Continuous variables entered the analysis as time
dependent with their median values per calendar
year. These median values were interpolated by using
linearregressionwithinpatients.Arterialhypertension
was defined as mean arterial blood pressure >107 mm
Hg or prescription of at least one antihypertensive
drug. Patients were classified as having coronary
heart disease if they had unstable angina or a myo-
cardialinfarctionorifcoronarystenosiswasdocumen-
ted by angiographyor radioisotopic techniques. Heart
failure, vascular disease, and diabetes were defined by
the attending physician.
Wedefinedacuterejectionconfirmedbybiopsyand
chronic allograft nephropathy according to Banff 93
and 97 criteria, respectively.
1011 A total of 3546 biop-
sies were obtained within the study period. Banff cri-
teria were initially not applied to 248 biopsies
performed before 1 January 1994. One of the investi-
gatorsreclassifiedthesebiopsiesaccordingtotheBanff
97 criteria. Acute rejection confirmed by biopsy was
defined as Banff borderline and higher grades/types
of cellular rejection. Diagnosis and grading of lesions
of biopsies in native kidneys and of the donor kidney
beforetransplantationwasperformedaccordingtothe
World Health Organization classification.
12
Data on immunosuppressive regimens were gath-
ered annually and classified into four groups: the stan-
dard immunosuppressive regimen was defined as
triple therapy with corticosteroids, mycophenolate
mofetil, and a calcineurin inhibitor (applied for 27.2%
of total graft life); triple therapy with corticosteroids,
azathioprine, and a calcineurin inhibitor (24.0% of
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Fig 1 | Percentage of users of erythropoietins by year.
Percentage for year x was computed as total time of use in
year x divided by total time at risk in year x
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graft life); and immunosuppression without calci-
neurin inhibitors (19.8% of graft life) or other (15.1%
of graft life). Induction treatment with a polyclonal
antibody was performed in 0.092% of total graft life.
IL-2 antibody induction was used infrequently (<1%).
Outcomes
The length of a patient’s survival was defined as the
time from the first kidney transplantation until death
or a second kidney transplantation or the end of the
study (31 December 2004), whichever came first, con-
ditional on survival to three months. Only death was
counted as event.
Characteristics of patients at the time of transplanta-
tion were described by mean and standard deviation,
by median and interquartile range, or by frequency
and percentage for normally distributed variables,
non-normally distributed variables, and categorical
variables,respectively.Weusedttests,Mann-Whitney
Table 1 |Characteristics of patients at day of transplantation, classified by use of erythropoietins. Values are means (SD),
medians (interquartile range), or numbers (percentages) as shown
Variable Erythropoietins No erythropoietins P value
No of patients
(erythropoietins /no
erythropoietins)
Age at transplantation (years) 48.6 (15.0) 48.7 (16.4) 0.889 1794 (805/989)
Donor age (years) 47.1 (15.3) 42 (15.8) <0.001 1597 (774/823)
Female donor 331 (42.5%) 347 (42%) 0.829 1606 (779/827)
Female recipient 350 (44.9%) 281 (34%) <0.001 1606 (779/827)
Years on dialysis before transplantation 1.8 (0.9-3.1) 1.8 (0.9-3) 0.871 1794 (805/989)
Year of transplantation 1998 (1995-2001) 1999 (1995- 2002) <0.001 1794 (805/989)
Body weight (kg) 71.3 (16) 71.5 (17.9) 0.837 1224 (575/649)
Haemoglobin concentration (g/l) 100 (91-110) 105 (96-116) <0.001 1572 (752/820)
STRF 191 (156-227) 192.1 (160-232.8) 0.388 1073 (545/528)
TRFS 24.2 (16.4-32.8) 23.6 (16.1-32.4) 0.431 1056 (538/518)
Panel reactive antibodies 0 (0-4) 0 (0-4) 0.728 1596 (779/817)
Sum of HLA mismatches 2.5 (1.3) 2.4 (1.3) 0.239 1542 (756/786)
Cold ischemia time (days) 16.4 (8.4) 16.8 (8) 0.332 1408 (694/714)
Type of immunosuppression:
S+MMF+CNI 180 (22.4) 188 (19) <0.001 1794 (805/989)
S+AZA+CNI 153 (19) 125 (12.6) <0.001 1794 (805/989)
S-free* 23 (2.9) 12 (1.2) <0.001 1794 (805/989)
Other† 449 (55.8) 664 (67.1) <0.001 1794 (805/989)
Induction therapy (ATG) 188 (23.4) 114 (11.5) <0.001 1794 (805/989)
CNI based 415 (80.7) 478 (83.7) 0.200 1085 (514/571)
Hypertension 730 (90.7%) 709 (71.7%) <0.001 1794 (805/989)
No of antihypertensive drugs prescribed 2 (1-4) 2 (0-3) <0.001 1794 (805/989)
Systolic arterial pressure (mm Hg) 140.3 (51.1) 118 (52) <0.001 1117 (513/604)
Diastolic arterial pressure (mm Hg) 82.2 (33.6) 70.2 (41.3) <0.001 1118 (513/605)
Cholesterol concentration (mmol/l) 5.26 (1.64) 5.10 (1.46) 0.046 1523 (736/787)
Coronary heart disease 132 (27.3%) 186 (29.5%) 0.410 1114 (484/630)
Heart failure 90 (18.6%) 107 (17%) 0.485 1114 (484/630)
Any heart disease 214 (45.1%) 283 (46.9%) 0.560 1077 (474/603)
Cerebrovascular disease 74 (16.1%) 70 (12%) 0.058 1045 (461/584)
Peripheral vascular disease 110 (23.9%) 132 (22.6%) 0.632 1045 (461/584)
Any vascular disease 153 (34.2%) 164 (29.9%) 0.149 997 (448/549)
Biopsy confirmed acute rejection 366 (46%) 250 (29.5%) <0.001 1642 (795/847)
Chronic allograft nephropathy 164 (20.4%) 75 (7.6%) <0.001 1794 (805/989)
Cadaveric donor 736 (91.4%) 855 (86.5%) 0.001 1794 (805/989)
Diabetes 233 (28.9%) 299 (30.2%) 0.552 1794 (805/989)
Primary indication for transplantation:
Diabetes 166 (20.6%) 249 (25.2%) 0.023 1794 (805/989)
Immune mediated 102 (12.7%) 121 (12.2%) 0.781 1794 (805/989)
PCKD 90 (11.2%) 124 (12.5%) 0.378 1794 (805/989)
Other or unknown 444 (55.2%) 485 (49.0%) 0.010 1794 (805/989)
ATG=antithymocyte globulin; STRF=serum transferrin concentration; TRFS=transferrin saturation; S+MMF+CNI=triple therapy with corticosteroids,
mycophenolate mofetil, and calcineurin inhibitor; S+AZA+CNI=triple therapy with corticosteroids, azathioprine, and CNI.
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2 tests to compare these characteristics
between patients who did or did not receive erythro-
poietins at any time after transplantation.
We computed extended Kaplan-Meier curves (tak-
ing into account time varying group membership of
individuals) to compare the survival of patients who
did and did not receive erythropoietins.
13
Multivariable Cox regression was used to model the
association of use of erythropoietins and haemoglobin
concentration (both time dependent) on survival.
14 As
the interaction of erythropoietins and haemoglobin
concentration must be assumed to be non-linear, we
used restricted cubic splines with five knots placed at
the 5th, 25th, 50th, 75th, and 95th centiles for haemo-
globin concentration.
15 We assessed results by depict-
ing the hazard ratio of haemoglobin concentration
compared with a reference concentration of 125 g/l in
those who did and did not receive erythropoietins and
compared those who did and did not receive erythro-
poietins at various haemoglobin concentrations. The
analysis was further adjusted by variables that either
proved significant in a multivariable model (P<0.05)
or changed the log hazard ratio of erythropoietins or
haemoglobin concentration by more than 25% if we
excluded those variables from the analysis (purposeful
selection algorithm).
16 We assumed that any variables
not selected will not have had a relevant impact on our
conclusions. All variables (except baseline variables)
were entered as time dependent. Occasionally missing
valuesofcovariateswerereplacedinamultipleimputa-
tionanalysis, which wasaccompanied byananalysisof
sensitivity of the assumption of randomly missing
values (see appendix on bmj.com). Five imputed ver-
sions of the dataset were generated, with results com-
puted for each of those datasets; results were then
combined with Rubin’s rules.
17 The adequacy of the
multiple imputation approach was underlined by the
compatibility of its results to those of the complete
cases only analysis. The higher number of events in
the multiple imputation analysis, however, leads to a
higher stability of results and better control of con-
founding compared with the complete cases only ana-
lysis. Included baseline covariates were primary
indication for transplantation (diabetes, immune
mediated, polycystic kidney disease, other), age at
transplantation, year of transplantation, time on dialy-
sis,coldischaemiatime,ageofdonor,andsumofHLA
mismatches.Timedependentvariableswerenumberof
blood pressure lowering drugs, peripheral or cardio-
vascular diseases, coronary heart disease, heart failure,
mean arterial pressure, cholesterol concentration, type
ofimmunosuppressivetreatment,presenceofdiabetes,
and dialysis status (functioning graft or graft not func-
tioning and patient needs dialysis again). In the final
model,weinvestigatedthelinearityassumptionofcon-
tinuous variables by likelihood ratio tests of a model
using restricted cubic splines for these variables against
a model with the variable entering as linear. We tested
theproportionalhazardsassumptionbytestinganinter-
action of each variable with log of time. Interactions of
variables were tested by including pair-wise product
interaction terms. These model assumptions tests were
performedbycontrollingafalsediscoveryrateof5%.
18
For all other hypothesis tests we considered P<0.05 as
significant, and all tests were two sided. All statistical
computations were done with SAS System V9.2
(2008,SASInstitute,Cary,NC).Allgraphicswerepro-
duced with the R software (www.r-project.org).
RESULTS
Table 1showsthecharacteristicsofthestudypatientsat
the time of transplantation, stratified for use of erythro-
poietins at any time during follow-up. Characteristics
associated with erythropoietins were older donor,
female recipient, lower haemoglobin concentration,
presence of hypertension, severity of hypertension (as
measuredbynumberofprescribedbloodpressurelow-
ering drugs and arterial pressure), higher cholesterol
concentration,chronicallograftnephropathy,andcada-
veric donor. Patients who received erythropoietins
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tionconfirmedbybiopsy(46%v30%).Inthesepatients
it is impossible to ascertain exactly whether such rejec-
tion occurred before or after use of erythropoietins. In
all further analysis, we analysed use of erythropoietins
by current prescription, which allows for individuals
who switch from use to non-use (n=314, 18%) or vice
versa (n=284, 16%).
Themedianfollow-uptimewas5.6years(interquartile
range3.0-8.7years).Figure1showsthepercentageofuse
of erythropoietins during the years under investigation.
Wenoticeincreasingprevalenceoferythropoietinsfrom
1992 (12%) to 2001 (28%), and a constant use thereafter.
Figure2showshaemoglobinconcentrationsoverfollow-
up, stratified for use of erythropoietins.
During follow-up, 345 of the 1794 patients died; 59
died during the first 90 days after transplantation. The
overall absolute mortality rates per 100 person years
were 5.4 for those who received erythropoietins and
2.6 for those who did not. The mortality rates for
cardiovascular, malignancy, and infection related
death were numerically higher in those who received
erythropoietins compared with those who did not
(events per 100 person years were 1.4 v 0.8 for cardio-
vascular events; 0.4 v 0.3 for malignancy; 1.7 v 0.7 for
infection). In total, 178 patients experienced graft fail-
ure (18 during the first 90 days) and returned to dialy-
sis. Figure 3 shows extended Kaplan-Meier estimates
of survival probabilities (allowing for individuals
switching groups) stratified for use of erythropoietins.
UsingmultivariableCoxregression,weassessedthe
association between haemoglobin concentration and
use of erythropoietins on survival. The purposeful
selection algorithm identified several variables to
include in the model. These comprised dialysis status,
cerebrovascular disease, peripheral vascular disease,
coronary heart disease, heart failure, cholesterol
concentration, type of immunosuppressive regimen,
diabetes status, age at transplantation, and cold ischae-
mia time.
Figure4showsthehazardratiosassociatedwithvar-
ious haemoglobin concentrations against a reference
level of 125 g/l for those who did and did not receive
erythropoietins.Inbothgroups,haemoglobinconcen-
trations<125g/lwerecorrelatedwithincreasedriskof
mortality.Inpatientswhodidnotreceiveerythropoie-
tins,higherconcentrationsledtoreducedrisk.Inthose
who did receive erythropoietins, however, we saw the
opposite: at haemoglobin concentrations >140 g/l, we
noted a significantly increased risk. Comparing these
patients with those who did not receive erythropoie-
tins, given they exhibit similar haemoglobin concen-
trations (fig 5), we found no significant difference in
mortality with haemoglobin concentrations up to
about 147 g/l, but with higher concentrations recipi-
ents had significantly higher risk than non-recipients.
Table 2 summarises these findings.
Several sensitivity analyses assessed the impact of
the model’s assumptions on our conclusions. In parti-
cular,wecheckedtheassumptionofrandomlymissing
values in the multiple imputation procedure, non-lin-
ear effects of metric variables, and time dependent
effects of variables, using a reduced or extended set of
covariables in the multivariable Cox model, and the
impact of including deaths during the first 90 days in
the analysis. Detailed reports of these additional
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of these sensitivity analyses led to any substantial
changes in our conclusions.
DISCUSSION
Regardlessoftreatmentwitherythropoietins,anaemia
in kidney transplant recipients is associated with an
increased risk of mortality. The hazard of dying
decreases numerically with increasing haemoglobin
concentration above the reference value of 125 g/l in
thosewhodonotreceiveerythropoietinsbutincreases
whenhigherconcentrationsareachievedwitherythro-
poietins. The cut-off where this difference in mortality
reached significance was a haemoglobin serum con-
centrationof>140g/l(lower95%confidenceinterval);
thepointestimateofthehazardratiostartedtoincrease
already at a haemoglobin concentration of 125 g/l.
Winkelmayr and Chandraker recently summarised
the enigma of post-transplant anaemia.
19 Their conclu-
sionwasthatbecauseofthelackoflarge,welldesigned,
prospective studies, the consequences of anaemia, the
responsetotreatment,andthecosteffectivenessoftreat-
ment in the post-transplantation setting remain poorly
understood. In a previous study the same authors con-
cluded that post-transplant anaemia is prevalent and
undertreated in kidney transplant recipients.
20
Comparison with other studies
Our results fit well with the data obtained in large ran-
domised controlled trials in patients with chronic kid-
ney disease and haemodialysis patients in whom a
target haemoglobin concentration of 135 g/l
(CHOIR)and130-150g/l(CREATE)oranormalver-
sus a low packed cell volume of 0.42 versus 0.30 (Nor-
malHematocritStudy)causedanincreaseoratleastno
decrease in cardiovascular mortality and morbidity.
Observational studies have previously shown that
anaemia after renal transplantation, defined as haemo-
globinconcentrationbelow130g/linmalesand120g/
l in females, is associated with higher mortality and
graft loss compared with non-anaemic patients.
2122
These studies, however, did not address the main
issue of treating anaemia with erythropoietins, and the
association of achieved haemoglobin concentrations
with hard outcomes such as mortality. Iron deficiency
contributes to post-transplant anaemia.
19 Measures of
iron status, such as transferring and transferrin satura-
tion of ferritin, were available and were no different
between groups but, according to Lorenz and collea-
gues, do not predict post-transplant anaemia.
23
Study limitations and strengths
Our present observational study has some intrinsic
limitations by design. We dealt with confounding of
the association of haemoglobin concentrations and
use of erythropoietins with survival by using techni-
ques such as the purposeful selection algorithm.
Unmeasured confounding was addressed by inclusion
of as many potentially relevant covariates as possible.
Asouraimwasnottocomparethosewhowereorwere
nottreatedwitherythropoietinsbutrathertoassessthe
association of achieved haemoglobin concentration
withsurvival,recentlydevelopedtechniquestocontrol
confounding and assess causality of effects, such as
marginal structural models, were not applicable.
24
Therefore, as in all non-randomised trials, we could
not confirm a causal relation. Furthermore, the
OEDTR database does not have information on dose
of erythropoietins and specific product and thus we
cannot speculate on what might have caused this
increased risk of mortality. A potential dilution effect
might have occurred because of patients who received
erythropoietinsbutdidnotrespond.Intheabsenceofa
randomised controlled trial, however, it is impossible
to quantify this dilution effect. Recent experimental
datainpatientsnotundergoingtransplantationsuggest
that high doses of erythropoietins might cross activate
growth receptor thus leading to tumour progression
and potential cardiovascular events.
25
Although all covariates entered the analysis as time
dependent, there was no general follow-up scheme at
which measurements were taken, which is typical for
observationalretrospectivestudies.Somedata,suchas
dataondrugprescriptionorcomorbidities,wereavail-
able only on an annual basis. For laboratory variables,
typically several measurements a year were available.
We paid regard to varying number of follow-up mea-
surementsbetweenpatientsby usingthe medianvalue
per calendar year. Some authors, such as Brown and
colleagues,
26 proposed analysis of longitudinal mea-
surements and survival in a so called joint regression
analysis. To our knowledge, such techniques have not
yet been used to analyse interactions of several time
dependent variables (as in our study) and are still far
from being suitable for routine analyses. Moreover, in
20variablesonaverage19.5%ofthevaluesweremiss-
ing. We addressed this problem with different analyti-
cal strategies including complete cases only and
multiple imputations including sensitivity analysis.
Results were stable over these different analyses, sug-
gesting robust findings. The occurrence of missing
values, however, must be seen as a limitation. In the
absence of a randomised controlled trial our analysis
providesthe only evidence on the association of use of
erythropoietins above a certain haemoglobin concen-
tration and mortality in renal transplant patients.
Table 2 |Adjusted* hazard ratios and 95% confidence intervals from multivariable Cox
regression including interaction of use of erythropoietins and haemoglobin concentration
(with restricted cubic splines with five knots)
Haemoglobin
concentration (g/l) No erythropoietins Erythropoietins
Erythropoietins v no
erythropoietins
95 3.5 (2.0 to 6.0) 8.0 (3.1 to 20.6) 1.4 (0.9 to 1.9)
110 2.5 (1.5 to 4.0) 4.7 (2.1 to 10.5) 1.1 (0.7 to 1.7)
125 1 (reference) 1 (reference) 0.6 (0.2 to 1.5)
140 0.7 (0.4 to 1.5) 2.8 (1.0 to 7.9) 2.2 (0.8 to 6.0)
155 0.7 (0.3 to 1.6) 4.7 (1.4 to 16.2) 3.8 (1.3 to 10.9)
*Adjusted for dialysis status, cerebrovascular disease, peripheral vascular disease, coronary heart disease,
heart failure, cholesterol concentration, type of immunosuppressive regimen, use of calcineurin inhibitors,
diabetes status, age at transplantation, cold ischaemia time.
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In summary we found that increasing haemoglobin
concentrationtoabove140g/lwithtreatmentwithery-
thropoietins in renal transplant recipients is associated
with an increase in mortality. Because of the study
designwecannotconfirma causalrelation,but,inana-
logytointerventionalstudiesinpatientswithadvanced
chronic kidney disease, we consider that renal trans-
plant recipients with a haemoglobin concentration
over 125 g/l should not be given erythropoietins.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
The prevalence of anaemia after kidney transplantation approaches 40% and about 20% of
severely anaemic patients (haemoglobin ≤110 g/l in males and 100 g/l in females) are
treated with erythropoietins
Recentdatasuggestthatuse oferythropoietins might actuallyincreasemortality undersome
circumstances
WHAT THIS STUDY ADDS
Increasing haemoglobin concentrations to >125 g/l with erythropoietins in renal transplant
recipients is associated with an increase in mortality, which was significant at >140 g/l
Theriskofdeathatanachievedhaemoglobinconcentrationof140g/lv125g/lwas 2.8with
erythropoietins and 0.7 without
Because of the study design a causal relation cannot be confirmed
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